Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29.904
Filter
1.
Mult Scler Relat Disord ; 87: 105647, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38838422

ABSTRACT

BACKGROUND: Observational studies looking at clinical a++nd MRI outcomes of treatments in pediatric MS, could assess current treatment algorithms, and provide insights for designing future clinical trials. OBJECTIVE: To describe baseline characteristics and clinical and MRI outcomes in MS patients initiating ocrelizumab and fingolimod under 18 years of age. METHODS: MS patients seen at 12 centers of US Network of Pediatric MS were included in this study if they had clinical and MRI follow-up and started treatment with either ocrelizumab or fingolimod prior to the age of 18. RESULTS: Eighty-seven patients initiating fingolimod and 52 initiating ocrelizumab met the inclusion criteria. Before starting fingolimod, mean annualized relapse rate was 0.43 (95 % CI: 0.29 - 0.65) and 78 % developed new T2 lesions while during treatment it was 0.12 (95 % CI: 0.08 - 1.9) and 47 % developed new T2 lesions. In the ocrelizumab group, the mean annualized relapse rate prior to initiation of treatment was 0.64 (95 % CI: 0.38-1.09) and a total of 83 % of patients developed new T2 lesions while during treatment it was 0.09 (95 % CI: 0.04-0.21) and none developed new T2 lesions. CONCLUSION: This study highlights the importance of evaluating current treatment methods and provides insights about the agents in the ongoing phase III trial comparing fingolimod and ocrelizumab.


Subject(s)
Antibodies, Monoclonal, Humanized , Fingolimod Hydrochloride , Magnetic Resonance Imaging , Humans , Fingolimod Hydrochloride/adverse effects , Fingolimod Hydrochloride/therapeutic use , Fingolimod Hydrochloride/administration & dosage , Female , Male , Adolescent , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Child , Immunologic Factors/adverse effects , Immunologic Factors/administration & dosage , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/administration & dosage , Multiple Sclerosis/drug therapy , Multiple Sclerosis/diagnostic imaging , Treatment Outcome , Brain/diagnostic imaging , Brain/drug effects , Brain/pathology
3.
Int J Biol Macromol ; 272(Pt 1): 132861, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38838884

ABSTRACT

Semen Coicis (S. Coicis) has been regarded as a valuable source of traditional herbal medicine in China for thousands of years. S. Coicis polysaccharides (SCPs) are one of the most important bioactive ingredients of S. Coicis, which have attracted worldwide attention, because of their great marketing potential and development prospects. Hot water extraction is currently the most commonly used method to isolate SCPs. The structural characteristics of SCPs have been extensively investigated through various advanced modern analytical techniques to dissect the structure-activity relationships. SCPs are mainly composed of diverse monosaccharides, from which Rha and Ara are the most prevalent glycosyl groups. In addition, the structures of SCPs are found to be closely related to their multiple biological activities, including antioxidant activity, immunomodulatory function, antitumor activity, hypoglycemic effect, intestinal microbiota regulatory activity, anti-inflammatory activity, among others. In view of this, this review aimed to provide systematic and current information on the isolation, structural characteristics, and bioactivities of SCPs to support their future applications as therapeutic agents and functional foods.


Subject(s)
Polysaccharides , Polysaccharides/chemistry , Polysaccharides/pharmacology , Polysaccharides/isolation & purification , Antioxidants/pharmacology , Antioxidants/chemistry , Antioxidants/isolation & purification , Humans , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/isolation & purification , Animals , Structure-Activity Relationship , Monosaccharides/analysis , Monosaccharides/chemistry , Immunologic Factors/pharmacology , Immunologic Factors/chemistry , Immunologic Factors/isolation & purification
4.
Carbohydr Polym ; 340: 122259, 2024 Sep 15.
Article in English | MEDLINE | ID: mdl-38858019

ABSTRACT

Our previous investigations have successfully identified the repeating structural units of EPS53, an exopolysaccharide derived from Streptococcus thermophilus XJ53 fermented milk, and substantiated its potential immunomodulatory properties. The present study further elucidated the structural characteristics of EPS53 and investigated the underlying mechanisms governing its in vitro immunoreactivity as well as its in vivo immunoreactivity. The results obtained from multi-detector high performance gel filtration chromatography revealed that EPS53 adopted a rigid rod conformation in aqueous solution, with the weight-average molecular weight of 1464 kDa, the number-average molecular weight of 694 kDa, and the polydispersity index of 2.11. Congo red experiment confirmed the absence of a triple helix conformation. Scanning electron microscopy showed that EPS53 displayed a three-dimensional fibrous structure covered with flakes. The in vitro findings indicated that EPS53 enhanced phagocytosis ability, reactive oxygen species (ROS) production, and cytokine levels of macrophages via the TLR4-mediated NF-κB/MAPK signaling pathways as confirmed by immunofluorescence staining experiments, inhibition blocking experiments, and Western blot assay. Additionally, the in vivo experiments demonstrated that EPS53 significantly increased macrophage and neutrophil number while enhancing NO and ROS levels in zebrafish larvae; thus, providing further evidence for the immunomodulatory efficacy of EPS53.


Subject(s)
Phagocytosis , Polysaccharides, Bacterial , Streptococcus thermophilus , Zebrafish , Animals , Polysaccharides, Bacterial/chemistry , Polysaccharides, Bacterial/pharmacology , Mice , RAW 264.7 Cells , Phagocytosis/drug effects , Toll-Like Receptor 4/metabolism , NF-kappa B/metabolism , Reactive Oxygen Species/metabolism , Macrophages/drug effects , Macrophages/metabolism , Cytokines/metabolism , Immunologic Factors/pharmacology , Immunologic Factors/chemistry , Immunomodulating Agents/pharmacology , Immunomodulating Agents/chemistry , Signal Transduction/drug effects
5.
BMJ Open Ophthalmol ; 9(1)2024 Jun 17.
Article in English | MEDLINE | ID: mdl-38886120

ABSTRACT

BACKGROUND: Graves' ophthalmopathy is a complex autoimmune disorder that can significantly affect quality of life (QoL), vision and physical appearance. Recently, a deeper understanding of the underlying pathogenesis has led to the development of novel treatment options. AIMS: The purpose of this review is to explore the current literature on conventional and novel treatment modalities and to evaluate which interventions provide the most favourable psychological and clinical outcomes in patients with moderate to severe, active Grave's ophthalmopathy. For example, QoL is an important psychosocial outcome of disease management. However, available literature demonstrates that not all clinically effective treatment options improve patients' QoL. METHODS: A systematic literature review was conducted to assess the clinical and psychosocial outcomes of different therapies for Graves' ophthalmopathy. An extensive database search of Ovid Medline, Ovid Embase and Cochrane Central Register of Controlled Trials was conducted. Studies generated were reviewed and the relevant selected data were retrieved and analysed. RESULTS: Results showed intravenous steroids, rituximab (RTX), tocilizumab and teprotumumab were all significantly effective in improving Clinical Activity Scores. Orbital radiotherapy showed a slight improvement in proptosis and diplopia. All interventions were safe with few serious adverse events being reported across all studies. All treatment modalities demonstrated beneficial improvements in both components of the Graves' Ophthalmopathy-QoL (QoL) questionnaire, apart from orbital radiotherapy which only demonstrated improvements in the visual functioning subscale. Teprotumumab was identified to be the most effective intervention for improving both clinical and psychosocial outcomes. However, further research needs to be conducted to evaluate its side effect profile and cost-effectiveness. Nonetheless, with time it has the potential to be a first-line treatment option in the management of active moderate to severe Graves' ophthalmopathy.


Subject(s)
Graves Ophthalmopathy , Quality of Life , Humans , Graves Ophthalmopathy/therapy , Graves Ophthalmopathy/psychology , Antibodies, Monoclonal, Humanized/therapeutic use , Rituximab/therapeutic use , Immunologic Factors/therapeutic use , Glucocorticoids/therapeutic use
6.
Int J Mol Sci ; 25(11)2024 May 28.
Article in English | MEDLINE | ID: mdl-38892082

ABSTRACT

Mucosal-associated invariant T (MAIT) cells, a subset of Vα7.2+ T cells, are a crucial link between innate and adaptive immunity, responding to various stimuli through TCR-dependent and independent pathways. We investigated the responses of MAIT cells and Vα7.2+/CD161- T cells to different stimuli and evaluated the effects of Cyclosporin A (CsA) and Vitamin D3 (VitD). Peripheral blood mononuclear cells (PBMCs) from healthy donors were stimulated with various agents (PMA/Ionomycin, 5-OP-RU, 5-OP-RU/IL-12/IL-33) with or without CsA and VitD. Flow cytometric analysis assessed surface markers and intracellular cytokine production. Under steady-state conditions, MAIT cells displayed elevated expression of CCR6 and IL-13. They showed upregulated activation and exhaustion markers after activation, producing IFNγ, TNFα, and TNFα/GzB. CsA significantly inhibited MAIT cell activation and cytokine production. Conversely, Vα7.2+/CD161- T cells exhibited distinct responses, showing negligible responses to 5-OP-RU ligand but increased cytokine production upon PMA stimulation. Our study underscores the distinct nature of MAIT cells compared to Vα7.2+/CD161- T cells, which resemble conventional T cells. CsA emerges as a potent immunosuppressive agent, inhibiting proinflammatory cytokine production in MAIT cells. At the same time, VitD supports MAIT cell activation and IL-13 production, shedding light on potential therapeutic avenues for immune modulation.


Subject(s)
Mucosal-Associated Invariant T Cells , NK Cell Lectin-Like Receptor Subfamily B , Humans , Mucosal-Associated Invariant T Cells/immunology , Mucosal-Associated Invariant T Cells/metabolism , Mucosal-Associated Invariant T Cells/drug effects , NK Cell Lectin-Like Receptor Subfamily B/metabolism , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Immunologic Factors/pharmacology , Cytokines/metabolism , Cyclosporine/pharmacology , Cholecalciferol/pharmacology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/immunology
7.
Carbohydr Polym ; 339: 122214, 2024 Sep 01.
Article in English | MEDLINE | ID: mdl-38823900

ABSTRACT

The polysaccharide, RGP2, was isolated from Russula griseocarnosa and its immunostimulatory effects were confirmed in cyclophosphamide (CTX)-induced immunosuppressed mice. Following purification via chromatography, structural analysis revealed that RGP2 had a molecular weight of 11.82 kDa and consisted of glucose (Glc), galactose (Gal), mannose, glucuronic acid and glucosamine. Bond structure analysis and nuclear magnetic resonance characterization confirmed that the main chain of RGP2 was formed by →6)-ß-D-Glcp-(1→, →3)-ß-D-Glcp-(1→ and →6)-α-D-Galp-(1→, which was substituted at O-3 of →6)-ß-D-Glcp-(1→ by ß-D-Glcp-(1→. RGP2 was found to ameliorate pathological damage in the spleen and enhance immune cell activity in immunosuppressed mice. Based on combined multiomics analysis, RGP2 altered the abundance of immune-related microbiota (such as Lactobacillus, Faecalibacterium, and Bacteroides) in the gut and metabolites (uridine, leucine, and tryptophan) in the serum. Compared with immunosuppressed mice, RGP2 also restored the function of antigen-presenting cells, promoted the polarization of macrophages into the M1 phenotype, positively affected the differentiation of helper T cells, and inhibited regulatory T cell differentiation through the protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway, ultimately exerting an immune boosting function. Overall, our findings highlight therapeutic strategies to alleviate CTX-induced immunosuppression in a clinical setting.


Subject(s)
Basidiomycota , Cell Differentiation , Glucans , Animals , Mice , Basidiomycota/chemistry , Glucans/chemistry , Glucans/pharmacology , Glucans/isolation & purification , Cell Differentiation/drug effects , T-Lymphocytes/drug effects , Immunomodulating Agents/pharmacology , Immunomodulating Agents/chemistry , Male , Immunologic Factors/pharmacology , Immunologic Factors/chemistry , Immunologic Factors/isolation & purification , Cyclophosphamide/pharmacology , Mice, Inbred BALB C , Gastrointestinal Microbiome/drug effects
8.
BMJ Case Rep ; 17(6)2024 Jun 26.
Article in English | MEDLINE | ID: mdl-38926127

ABSTRACT

Autoimmune haemolytic anaemia (AIHA), autoimmune destruction of erythrocytes is most commonly secondary to immunomodulated conditions. The association between AIHA and inflammatory bowel disease (IBD) has been poorly investigated. We aim to report a case of AIHA in a patient with ulcerative colitis (UC) treated with vedolizumab.A case of a woman in her 30s with UC that after the initiation of vedolizumab developed severe anaemia. Due to the absence of visible blood losses and a positive Coombs direct test, the diagnosis of AIHA was established. The patient initially initiated prednisolone with no response. Rituximab had to be introduced. After a few days with this therapy, there was a clinical and analytical improvement.AIHA must be taken into account as a possible cause of anaemia in patients with IBD. The differential diagnosis between IBD or drug-related (namely vedolizumab) as the cause of the AIHA is complex and almost impossible to establish.


Subject(s)
Anemia, Hemolytic, Autoimmune , Antibodies, Monoclonal, Humanized , Colitis, Ulcerative , Gastrointestinal Agents , Rituximab , Humans , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/complications , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Female , Anemia, Hemolytic, Autoimmune/chemically induced , Anemia, Hemolytic, Autoimmune/drug therapy , Anemia, Hemolytic, Autoimmune/diagnosis , Adult , Rituximab/therapeutic use , Rituximab/adverse effects , Gastrointestinal Agents/therapeutic use , Gastrointestinal Agents/adverse effects , Immunologic Factors/therapeutic use , Immunologic Factors/adverse effects , Treatment Outcome
9.
Zhongguo Ying Yong Sheng Li Xue Za Zhi ; 40: e20240004, 2024 Jun 21.
Article in English | MEDLINE | ID: mdl-38902996

ABSTRACT

The human immune system plays a pivotal role in protecting the body against pathogens, maintaining homeostasis, and preventing disease. Immunomodulation, the process of regulating immune responses, is crucial for optimal health. In recent years, there has been growing interest in natural remedies for immune system modulation, driven by the recognition of their potential efficacy and safety profiles. This project aims to investigate the immunomodulatory effects of drumstick leaves tablets, derived from Moringa oleifera, a plant known for its rich nutritional and medicinal properties. The study will explore the potential of drumstick leaves tablets to modulate immune responses through in vitro and in vivo experiments. Through comprehensive analysis of the immunomodulatory properties of drumstick leaves tablets, this project aims to contribute to our understanding of natural remedies for immune system modulation. The findings could have significant implications for the development of novel therapeutic interventions aimed at enhancing immune function and improving human health.


Subject(s)
Immunomodulating Agents , Moringa oleifera , Plant Leaves , Tablets , Moringa oleifera/chemistry , Plant Leaves/chemistry , Immunomodulating Agents/pharmacology , Animals , Immunologic Factors/pharmacology , Mice , Humans , Drugs, Chinese Herbal/pharmacology
10.
Front Immunol ; 15: 1390997, 2024.
Article in English | MEDLINE | ID: mdl-38919606

ABSTRACT

Background: The incidence of severe infections (SIs) in patients with autoimmune nephropathy after rituximab (RTX) treatment varies significantly. Our study aims to identify high-risk populations, specifically by comparing the differences in the risk of SIs between patients with primary nephropathy and those with nephropathy in the context of systemic autoimmune diseases (referred to as secondary nephropathy). Methods: This retrospective cohort study investigated the occurrence of SIs in adult patients with immune-related kidney disease who received RTX treatment at our institution from 2017 to 2022. Multivariable COX regression models were used to analyze the association between the type of nephropathy (primary or secondary) and SIs. Propensity score analyses, subgroup analyses, and E-value calculations were performed to ensure the reliability of the results. Results: Out of 123 patients, 32 (26%) developed 39 cases of SIs during a mean follow-up period of 19.7 ± 14.6 months post-RTX treatment, resulting in an incidence rate of 18.9/100 patient-years. The multivariable COX regression analysis indicated that patients with secondary nephropathy had a significantly higher risk of SIs compared to those with primary nephropathy (HR = 5.86, 95% CI: 1.05-32.63, P = 0.044), even after accounting for confounding variables including gender, age, BMI, history of prior SIs, baseline eGFR, lymphocyte counts, IgG levels, and the utilization of other immunosuppressive therapies. Various sensitivity analyses consistently supported these findings, with an E-value of 5.99. Furthermore, advanced age (HR: 1.03; 95% CI: 1.01-1.06; P = 0.023), low baseline IgG levels (HR: 0.75; 95% CI: 0.64-0.89; P < 0.001), and recent history of SIs (HR: 5.68; 95% CI: 2.2-14.66; P < 0.001) were identified as independent risk factors. Conclusion: The incidence of SIs following RTX administration in patients with autoimmune nephropathy is significant. It is crucial to note that there are distinct differences between the subgroups of primary and secondary nephropathy. Patients with secondary nephropathy, particularly those who are elderly, have low baseline IgG levels, and have a recent history of SI, are more susceptible to SIs.


Subject(s)
Rituximab , Humans , Rituximab/adverse effects , Rituximab/therapeutic use , Male , Female , Retrospective Studies , Middle Aged , Aged , Adult , Incidence , Infections/etiology , Infections/epidemiology , Autoimmune Diseases/drug therapy , Autoimmune Diseases/epidemiology , Risk Factors , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , Kidney Diseases/etiology , Kidney Diseases/epidemiology , Kidney Diseases/chemically induced
11.
Molecules ; 29(12)2024 Jun 11.
Article in English | MEDLINE | ID: mdl-38930835

ABSTRACT

Ginseng (Panax ginseng C.A. Mey) is known for its rich saponin compounds and tonic effects. To better utilize the medicinal value of ginseng, this study investigated the extraction process, components, free radical scavenging ability, and immunomodulatory activity of total saponins of ginseng fibrous roots. The response surface methodology was employed to optimize the extraction process of total saponins, and Q-Orbitrap high-resolution liquid chromatography-mass spectrometry (LC-MS) was used to identify the chemical constituents in the total saponins extract of ginseng fibrous roots (GRS). The results showed that the optimal extraction process was achieved with an ethanol concentration of 68%, a material-solvent ratio of 1:25 mL/g, and an extraction time of 20 min, yielding a total saponin content of 6.34% under these conditions. The extract contained four terpenoid compounds and four polyphenolic compounds. GRS exhibited considerable scavenging activity against DPPH and ABTS radicals, with IC50 values of 0.893 and 0.210 mg/mL, respectively. Moreover, GRS restored immune suppression in mice by increasing white blood cell, red blood cell, and neutrophil counts, and improving the lymphocyte. It also promoted immune system recovery, as evidenced by elevated serum levels of IL-2, IFN-γ, TNF-α, and IL-1ß in mice. GRS is a natural compound with promising potential for developing antioxidants and immunomodulatory foods.


Subject(s)
Free Radical Scavengers , Panax , Plant Extracts , Plant Roots , Saponins , Panax/chemistry , Saponins/pharmacology , Saponins/chemistry , Saponins/isolation & purification , Free Radical Scavengers/pharmacology , Free Radical Scavengers/chemistry , Plant Roots/chemistry , Animals , Mice , Plant Extracts/chemistry , Plant Extracts/pharmacology , Immunologic Factors/pharmacology , Immunologic Factors/chemistry , Immunomodulating Agents/pharmacology , Immunomodulating Agents/chemistry , Antioxidants/pharmacology , Antioxidants/chemistry
12.
Neurol Neuroimmunol Neuroinflamm ; 11(4): e200264, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38870458

ABSTRACT

OBJECTIVES: To report CD19+ B-cell counts and possible adverse effects on infants of mothers exposed to anti-CD20 mAbs ≤6 months before/during pregnancy or lactation. METHODS: We conducted a retrospective study using data from the German nationwide neuroimmunologic pregnancy registry. Inclusion criteria involved infants whose mothers received anti-CD20 mAbs ≤6 months before/during pregnancy or lactation, with ≥1 postnatal CD19+ B-cell count. Main outcomes were absolute and relative CD19+ B-cell counts. Comparison with reference values was performed conservatively in a subgroup with maternal exposure ≤3 months before/during pregnancy. Additional outcomes included pregnancy results, severe infections, and lymphocyte counts. RESULTS: The cohort comprised 49 infants (F:M 25:24) exposed to anti-CD20 mAbs ≤6 months before/during pregnancy or lactation. CD19+ B-cell and lymphocyte counts in 40 infants with maternal exposure ≤3 months before/during pregnancy were comparable with normative values. Only 2 cases of complete CD19+ B-cell depletion occurred after second-trimester and third-trimester ocrelizumab exposure, with repopulation observed within 2 months. Exclusive lactation exposure had no significant effect on infants' absolute CD19+ B-cell counts. DISCUSSION: Administering anti-CD20 mAbs before or at the pregnancy onset, or during lactation, seems safe without significant impact on infant B-cell development. However, second-trimester or third-trimester exposure can cause CD19+ B-cell depletion due to placental transfer, necessitating monitoring and postponing live vaccines.


Subject(s)
Antigens, CD20 , B-Lymphocytes , Lactation , Humans , Female , Pregnancy , Infant, Newborn , B-Lymphocytes/immunology , B-Lymphocytes/drug effects , Retrospective Studies , Lactation/immunology , Male , Adult , Antigens, CD20/immunology , Infant Health , Prenatal Exposure Delayed Effects/immunology , Prenatal Exposure Delayed Effects/chemically induced , Antigens, CD19/immunology , Lymphocyte Count , Rituximab/adverse effects , Rituximab/administration & dosage , Rituximab/pharmacology , Immunologic Factors/adverse effects , Immunologic Factors/administration & dosage , Immunologic Factors/pharmacology , Infant
13.
Support Care Cancer ; 32(7): 407, 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38833106

ABSTRACT

OBJECTIVE: Poor adherence to oral chemotherapy adversely impacts clinical outcomes and escalates overall healthcare costs. Despite barriers to medication adherence, a significant gap remains in assessing adherence to oral chemotherapy among multiple myeloma (MM) patients with lower socioeconomic status. Hence, our study aims to evaluate immunomodulator adherence in MM patients at a county hospital, primarily serving underrepresented and indigent individuals with low socioeconomic status across the greater Houston area. METHODS: Inclusion criteria composed of patients diagnosed with MM, aged at least 18 years, and treated with lenalidomide or pomalidomide-two widely used immunomodulators-for a minimum of 2 months or having two or more records of dispensation between May 2019 and May 2021. Adherence was gauged using an adjusted version of the medication possession ratio (MPR). RESULTS: Sixty-two patients were enrolled, yielding a mean MPR value of 88% (SD, ± 18.9). Of these, 43 patients (69.3%) demonstrated adherence with an MPR of ≥ 0.90. A significant difference was found in treatment duration between the adherent (mean 8.8 months; SD, ± 7.2) and non-adherent (mean 13.4 months; SD, ± 7.9) groups (p = 0.027). Notably, race/ethnicity demonstrated a significant difference (p = 0.048), driven by disparities in African American and Hispanic representation across adherence levels. CONCLUSION: In summary, our findings highlight race and treatment duration to be predictors of immunomodulator adherence among MM patients with lower socioeconomic status. Further research is imperative to devise and test innovative interventions aimed at enhancing medication adherence, thereby contributing to improved survival and healthcare quality in this population.


Subject(s)
Lenalidomide , Medication Adherence , Multiple Myeloma , Social Class , Thalidomide , Humans , Multiple Myeloma/drug therapy , Male , Retrospective Studies , Medication Adherence/statistics & numerical data , Female , Middle Aged , Aged , Thalidomide/therapeutic use , Thalidomide/analogs & derivatives , Thalidomide/administration & dosage , Lenalidomide/administration & dosage , Lenalidomide/therapeutic use , Immunologic Factors/therapeutic use , Immunologic Factors/administration & dosage , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/administration & dosage , Immunomodulating Agents/pharmacology , Texas , Aged, 80 and over , Adult
14.
Neurol Neuroimmunol Neuroinflamm ; 11(4): e200251, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38838284

ABSTRACT

BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is considered a prototypic autoimmune disease of the CNS. It is the leading cause of chronic neurologic disability in young adults. Proinflammatory B cells and autoreactive T cells both play important roles in its pathogenesis. We aimed to study alterations of regulatory T cells (Tregs), which likely also contribute to the disease, but their involvement is less clear. METHODS: By combining multiple experimental approaches, we examined the Treg compartments in 41 patients with relapsing-remitting MS and 17 healthy donors. RESULTS: Patients with MS showed a reduced frequency of CD4+ T cells and Foxp3+ Tregs and age-dependent alterations of Treg subsets. Treg suppressive function was compromised in patients, who were treated with natalizumab, while it was unaffected in untreated and anti-CD20-treated patients. The changes in natalizumab-treated patients included increased proinflammatory cytokines and an altered transcriptome in thymus-derived (t)-Tregs, but not in peripheral (p)-Tregs. DISCUSSION: Treg dysfunction in patients with MS might be related to an altered transcriptome of t-Tregs and a proinflammatory environment. Our findings contribute to a better understanding of Tregs and their subtypes in MS.


Subject(s)
Multiple Sclerosis, Relapsing-Remitting , Natalizumab , T-Lymphocytes, Regulatory , Humans , T-Lymphocytes, Regulatory/immunology , Adult , Female , Male , Multiple Sclerosis, Relapsing-Remitting/immunology , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Natalizumab/pharmacology , Middle Aged , Thymus Gland/immunology , Immunologic Factors/pharmacology , Young Adult
15.
Food Res Int ; 189: 114573, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38876600

ABSTRACT

Food proteins and their peptides play a significant role in the important biological processes and physiological functions of the body. The peptides show diverse biological benefits ranging from anticancer to antihypertensive, anti-obesity, and immunomodulatory, among others. In this review, an overview of food protein digestion in the gastrointestinal tract and the mechanisms involved was presented. As some proteins remain resistant and undigested, the multifarious factors (e.g. protein type and structure, microbial composition, pH levels and redox potential, host factors, etc.) affecting their colonic fermentation, the derived peptides, and amino acids that evade intestinal digestion are thus considered. The section that follows focuses on the mechanisms of the peptides with anticancer, antihypertensive, anti-obesity, and immunomodulatory effects. As further considerations were made, it is concluded that clinical studies targeting a clear understanding of the gastrointestinal stability, bioavailability, and safety of food-based peptides are still warranted.


Subject(s)
Anti-Obesity Agents , Antihypertensive Agents , Antineoplastic Agents , Dietary Proteins , Digestion , Peptides , Humans , Antihypertensive Agents/pharmacology , Dietary Proteins/metabolism , Peptides/pharmacology , Antineoplastic Agents/pharmacology , Anti-Obesity Agents/pharmacology , Gastrointestinal Tract/metabolism , Animals , Immunologic Factors/pharmacology , Gastrointestinal Microbiome/drug effects , Biological Availability , Immunomodulating Agents/pharmacology
16.
ACS Appl Mater Interfaces ; 16(25): 32104-32117, 2024 Jun 26.
Article in English | MEDLINE | ID: mdl-38865210

ABSTRACT

The repair of infected wounds is a complex physiopathologic process. Current studies on infected wound treatment have predominantly focused on infection treatment, while the factors related to delayed healing caused by vascular damage and immune imbalance are commonly overlooked. In this study, an extracellular matrix (ECM)-like dynamic and multifunctional hyaluronic acid (HA) hydrogel with antimicrobial, immunomodulatory, and angiogenic capabilities was designed as wound dressing for the treatment of infected skin wounds. The dynamic network in the hydrogel dressing was based on reversible metal-ligand coordination formed between sulfhydryl groups and bioactive metal ions. In our design, antibacterial silver and immunomodulatory zinc ions were employed to coordinate with sulfhydrylated HA and a vasculogenic peptide. In addition to the desired bioactivities for infected wounds, the hydrogel could also exhibit self-healing and injectable abilities. Animal experiments with infected skin wound models indicated that the hydrogel dressings enabled minimally invasive injection and seamless skin wound covering and then facilitated wound healing by efficient bacterial killing, continuous inflammation inhibition, and improved blood vessel formation. In conclusion, the metal ion-coordinated hydrogels with wound-infection-desired bioactivities and ECM-like dynamic structures represent a class of tissue bionic wound dressings for the treatment of infected and chronic inflammation wounds.


Subject(s)
Anti-Bacterial Agents , Hydrogels , Wound Healing , Wound Healing/drug effects , Animals , Hydrogels/chemistry , Hydrogels/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Mice , Silver/chemistry , Silver/pharmacology , Hyaluronic Acid/chemistry , Hyaluronic Acid/pharmacology , Zinc/chemistry , Zinc/pharmacology , Immunologic Factors/chemistry , Immunologic Factors/pharmacology , Wound Infection/drug therapy , Wound Infection/pathology , Wound Infection/microbiology , Bandages , Humans , Neovascularization, Physiologic/drug effects , Staphylococcus aureus/drug effects , Ions/chemistry
17.
Sci Total Environ ; 944: 173823, 2024 Sep 20.
Article in English | MEDLINE | ID: mdl-38851341

ABSTRACT

Parabens are widely used as broad-spectrum anti-microbials and preservatives in food, cosmetics, pharmaceuticals, and personal care products. Studies suggest that the utilization of parabens has substantially increased over the past years, particularly during the global pandemic of coronavirus disease 2019 (COVID-19). Although parabens are generally recognized as safe by the U.S. FDA, some concerns have been raised regarding the potential health effects of parabens associated with immunotoxicity. Herein, we comprehensively investigated several key characteristics of immunotoxicants of five commonly used parabens (methyl-, ethyl-, propyl-, butyl-, and benzyl parabens) in human THP-1 derived macrophages, which are effector cells serving as a first line of host defense against pathogens and tumor immunosurveillance. The results indicate parabens, at concentrations found in humans and biota, significantly dampened macrophage chemotaxis and secretion of major pro-inflammatory cytokines (TNF-α and IL-6) and anti-inflammatory cytokine (IL-10), corroborating the mRNA expression profile. Furthermore, some parabens were found to markedly alter macrophage adhesion and cell surface expression of costimulatory molecules, CD80+ and CD86+, and significantly increase macrophage phagocytosis. Collectively, these findings heighten awareness of potential immunotoxicity posed by paraben exposure at biologically relevant concentrations, providing implications for human health and ecological risks associated with immune dysfunctions.


Subject(s)
Macrophages , Parabens , Parabens/toxicity , Humans , Macrophages/drug effects , Macrophages/immunology , THP-1 Cells , Immunologic Factors/toxicity , Cytokines/metabolism , COVID-19 , Preservatives, Pharmaceutical/toxicity
18.
J Nanobiotechnology ; 22(1): 320, 2024 Jun 08.
Article in English | MEDLINE | ID: mdl-38849820

ABSTRACT

Simultaneously modulating the inflammatory microenvironment and promoting local bone regeneration is one of the main challenges in treating bone defects. In recent years, osteoimmunology has revealed that the immune system plays an essential regulatory role in bone regeneration and that macrophages are critical components. In this work, a mussel-inspired immunomodulatory and osteoinductive dual-functional hydroxyapatite nano platform (Gold/hydroxyapatite nanocomposites functionalized with polydopamine - PDA@Au-HA) is developed to accelerate bone tissues regeneration by regulating the immune microenvironment. PDA coating endows nanomaterials with the ability to scavenge reactive oxygen species (ROS) and anti-inflammatory properties, and it also exhibits an immunomodulatory ability to inhibit M1 macrophage polarization and activate M2 macrophage secretion of osteogenesis-related cytokines. Most importantly, this nano platform promotes the polarization of M2 macrophages and regulates the crosstalk between macrophages and pre-osteoblast cells to achieve bone regeneration. Au-HA can synergistically promote vascularized bone regeneration through sustained release of Ca and P particles and gold nanoparticles (NPs). This nano platform has a synergistic effect of good compatibility, scavenging of ROS, and anti-inflammatory and immunomodulatory capability to accelerate the bone repair process. Thus, our research offers a possible therapeutic approach by exploring PDA@Au-HA nanocomposites as a bifunctional platform for tissue regeneration.


Subject(s)
Bivalvia , Bone Regeneration , Durapatite , Gold , Indoles , Macrophages , Osteogenesis , Bone Regeneration/drug effects , Durapatite/chemistry , Durapatite/pharmacology , Animals , Mice , Gold/chemistry , Gold/pharmacology , Bivalvia/chemistry , RAW 264.7 Cells , Macrophages/drug effects , Indoles/chemistry , Indoles/pharmacology , Osteogenesis/drug effects , Reactive Oxygen Species/metabolism , Polymers/chemistry , Polymers/pharmacology , Nanocomposites/chemistry , Metal Nanoparticles/chemistry , Osteoblasts/drug effects , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/chemistry , Immunologic Factors/pharmacology , Immunologic Factors/chemistry , Cytokines/metabolism
19.
Microb Pathog ; 192: 106719, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38810768

ABSTRACT

Cimicifugae rhizoma is a traditional Chinese herbal medicine in China, and modern pharmacological research showed that it has obvious antiviral activity. Many polysaccharides have been proved to have immune enhancement and antiviral activity, but there are few studies on the biological activity of Cimicifuga rhizoma polysaccharide (CRP). The aim was to explore the character of CRP and its effects on improving immune activity and inhibiting transmissible gastroenteritis virus (TGEV). The monosaccharide composition, molecular weight, fourier transform infrared spectra and electron microscopy analysis of CRP was measured. The effect of CRP on immune activity in lymphocytes and RAW264.7 cells were studied by colorimetry, FITC-OVA fluorescent staining and ELISA. The effect of CRP on TGEV-infected PK-15 cells was determined using Real-time PCR, Hoechst fluorescence staining, trypan blue staining, acridine orange staining, Annexin V-FITC/PI fluorescent staining, DCFH-DA loading probe, and JC-1 staining. Network pharmacology was used to predict the targets of CRP in enhancing immunity and anti-TGEV, and molecular docking was used to further analyze the binding mode between CPR and core targets. The results showed that CRP was mainly composed of glucose and galactose, and its molecular weight was 64.28 kDa. The content of iNOS and NO in CRP group were significantly higher than the control group. CRP (125 and 62.5 µg/mL) could significantly enhance the phagocytic capacity of RAW264.7 cells, and imprive the content of IL-1ß content compared with control group. 250 µg/mL of CRP possessed the significant inhibitory effect on TGEV, which could significantly reduce the apoptosis compared to TGVE group and inhibit the decrease in mitochondrial membrane potential compared to TGVE group. The mRNA expression of TGEV N gene in CRP groups was significantly lower than TGEV group. PPI showed that the core targets of immune-enhancing were AKT1, MMP9, HSP90AA1, etc., and the core targets of TGE were CASP3, MMP9, EGFR, etc. Molecular docking show that CRP has binding potential with target. These results indicated that CRP possessed the better immune enhancement effect and anti-TGEV activity.


Subject(s)
Antiviral Agents , Molecular Docking Simulation , Polysaccharides , Transmissible gastroenteritis virus , Animals , Mice , Polysaccharides/pharmacology , Polysaccharides/chemistry , RAW 264.7 Cells , Transmissible gastroenteritis virus/drug effects , Antiviral Agents/pharmacology , Rhizome/chemistry , Interleukin-1beta/metabolism , Molecular Weight , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type II/genetics , Cell Line , Lymphocytes/drug effects , Lymphocytes/immunology , Apoptosis/drug effects , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/chemistry , Spectroscopy, Fourier Transform Infrared , Monosaccharides , Nitric Oxide/metabolism , Immunologic Factors/pharmacology
20.
Fitoterapia ; 176: 105988, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38703915

ABSTRACT

Traditional medicinal plants have been used for centuries for their immunomodulatory properties and therapeutic potentials. The present study aims to investigate the immunomodulatory constituents from traditional medicinal plant, Tinospora cordifolia (willd.). Our study resulted in the isolation of new compound, 27-hydroxy octacosyl ferulate (1) along with eleven known compounds (2-12). The structures of the isolated compounds were characterized by combination of NMR (1D and 2D) and Mass spectroscopic methods. The hemisynthesis of compound 12 (ferulic acid) yielded (12a-12d and 12e-12 m) derivatives. Further, the isolated compounds and synthesized derivatives were assessed for their immunomodulatory potentials by evaluating their cytotoxicity and pro-inflammatory effects against macrophage cells (IL-6) and DC activation markers (CD 11c and 86). The biological results indicated that crude extract displayed potent immunomodulatory activity while isolated compounds and synthetic analogues showed moderate activity. Among the tested compounds, new compound (1), quercetin (10) and derivatives 12b, 12c found to be non-cytotoxic and displayed immunomodulatory potentials. Therefore, these compounds can be studied for autoimmunity and other immune suppressing conditions.


Subject(s)
Immunomodulating Agents , Phytochemicals , Tinospora , Tinospora/chemistry , Molecular Structure , Phytochemicals/pharmacology , Phytochemicals/isolation & purification , Animals , Mice , Immunomodulating Agents/pharmacology , Immunomodulating Agents/isolation & purification , Coumaric Acids/pharmacology , Coumaric Acids/isolation & purification , Immunologic Factors/pharmacology , Immunologic Factors/isolation & purification , RAW 264.7 Cells , Macrophages/drug effects , Plant Extracts/pharmacology , Plant Extracts/chemistry , Interleukin-6
SELECTION OF CITATIONS
SEARCH DETAIL
...